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Summary 29 
Objectives. IgM antibodies are usually the first to be produced during treponemal infection. 30 
Three commercially available enzyme immunoassays (EIA) for detection of IgM antibodies 31 
against Treponema pallidum were evaluated. 32 
Methods. Results of the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun), Pathozyme 33 
Syphilis-M Capture (Omega Diagnostics) and recomWell Treponema IgM (Mikrogen) were 34 
compared with those of the Treponema pallidum particle agglutination (TPPA) and the Venereal 35 
Disease Research Laboratory (VDRL) tests for 307 serum samples.  36 
Results. The overall sensitivity (95% confidence interval [CI]) of the TPPA was 100% (97.7-37 
100%) compared to 83.3% (76.5-88.8%) of the VDRL, 88.5% (82.4-93.0%) of the Pathozyme, 38 
84.6% (78.0-89.9) of the Euroimmun, and 73.6% (66.1-80.4%) of a modified recomWell test 39 
procedure. Specificities were in the range of 91.4-100%. In primary syphilis, sensitivities of the 40 
Pathozyme (89.8%; 95% CI, 79.2-96.2%) and Euroimmun tests (81.4%; 95% CI, 69.1-90.3%) 41 
were significantly higher (p < 0.05) than the sensitivity of the VDRL test (61%; 95% CI, 47.4-42 
73.5%). IgM EIAs even were positive in some cases of suspected very early infection where the 43 
VDRL was non-reactive and the TPPA was indeterminate. 44 
Conclusions. In cases of suspected early infection specific IgM EIAs should be used in addition 45 
to other screening tests. The VDRL is not recommended for screening. 46 
 47 
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Introduction 52 
Serology remains the mainstay of laboratory detection of Treponema pallidum infections. Two 53 
classes of antibody tests are available; treponemal and non-treponemal. In Europe, it is 54 
recommended to use a treponemal antigen test as a single screening test, e.g. an enzyme 55 
immunoassay (EIA) or the Treponema pallidum particle agglutination test (TPPA),1 with positive 56 
samples being confirmed by a second treponemal test. Non-treponemal tests, e.g. VDRL 57 
(Venereal Disease Research Laboratory) or RPR (Rapid Plasma Reagin), are useful for 58 
detection of active infection and for monitoring treatment response,2 however, they are less 59 
specific than treponemal tests and lack sensitivity in primary and late syphilis patients.2-5 60 
Additionally, they are labour intensive and cannot be run on automated platforms.  61 
IgM class antibodies are usually the first to be produced during treponemal infection.6 It 62 
has been shown that IgM-specific EIAs are very sensitive in detecting primary and secondary 63 
syphilis2,4,5,7-10 with the IgM EIA being the first test positive in some instances. It is 64 
recommended to request a specific anti-treponemal IgM test if primary syphilis is suspected.1,2 65 
Although many different commercial IgM EIA tests are available, few have been analysed for 66 
their performance at different stages of syphilis, namely the Mercia Syphilis M EIA (Microgen 67 
Products Ltd)4,5,8-12 the Eti-syphilis-M (DiaSorin)7 and the recomWell Treponema IgM 68 
(Mikrogen).13 Additionally, the Mercia Syphilis M EIA has been evaluated for diagnosing 69 
maternal and congenital syphilis14 and the use of Euroimmun EIA and Western-blot IgG and IgM 70 
assays for screening blood donors has been investigated.15 71 
In the present study, three commercially available EIAs to detect IgM antibodies to T. 72 
pallidum were evaluated (Anti-Treponema-pallidum-ELISA IgM, Euroimmun; Pathozyme 73 
Syphilis M Capture, Omega Diagnostics; recomWell Treponema IgM, Mikrogen). Sensitivities 74 
were determined with consecutive sera from untreated syphilis patients at different disease 75 
stages. Specificities were analysed by a panel of sera including sera of patients with diseases 76 
potentially interfering with syphilis serology tests. 77 
 78 
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 79 
Material and Methods 80 
Study design 81 
156 consecutive sera submitted to the syphilis serology laboratory at the Clinic of Dermatology, 82 
University Hospital of Zurich of patients at the Zurich University Hospital which were diagnosed 83 
between January 2008 and December 2010 having untreated syphilis were included in this 84 
retrospective study. 85 
Routine testing included the VDRL test (Dade Behring, Düdingen, Germany), the TPPA 86 
test (Fujirebio Inc., Tokyo, Japan), the Fluorescent Treponemal Antibody-Absorption test (FTA-87 
ABS, Biomérieux, Genève, Switzerland), and the Pathozyme Syphilis M Capture EIA (Omega 88 
Diagnostic Ltd., Alva, United Kingdom). After routine testing, sera were stored at -20°C until 89 
further testing in 2011 with the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun, Lübeck, 90 
Germany) and the recomWell Treponema IgM (Mikrogen, Neuried, Germany). 91 
To assess the specificity, 151 sera were tested including sera known to be potentially 92 
cross-reactive (anti-Borrelia burgdorferi IgM [n = 10], anti-Epstein-Barr virus IgM [n = 10], anti-93 
Cytomegalovirus IgM [n = 10], auto-immune disease (Lupus erythematosus) [n = 1], HIV 94 
patients [n = 20] and pregnant women [n = 20]), negative sera without further specification (n = 95 
50) and sera of previously treated syphilis patients (n = 30). 96 
 97 
Patient characteristics 98 
Based on clinical data obtained from patients charts and serological results, patients were 99 
categorized as having primary syphilis (n = 59), secondary syphilis (n = 66), latent syphilis (n = 100 
25), or tertiary syphilis (n = 6) (Table 1). 50/59 primary syphilis patients had typical ulcers at 101 
ano-genital or oro-pharyngeal sites. The other nine patients had positive serology and 102 
erythematous lesions on the penis or the tonsils (n = 3) or a possible exposition to syphilis 103 
without clinic (n = 6). Secondary syphilis patients had muco-cutaneous skin lesions typical for 104 
secondary syphilis. Patients with latent syphilis had positive serology but without clinical signs of 105 
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syphilis. Patients were classified as having tertiary syphilis based on a combination of clinical 106 
and serological findings as well as CSF analysis 107 
 108 
Serological testing 109 
All tests were performed according to the manufacturer’s instructions. To avoid false-negative 110 
results due to the prozone phenomenon the VDRL was tested up to a 1:64 dilution. 111 
The three EIAs are designed for the semi-quantitative detection of IgM antibodies against T. 112 
pallidum. The Euroimmun Anti-Treponema-pallidum-ELISA (IgM) and the recomWell 113 
Treponema IgM both involve indirect ‘sandwich’ EIA procedures using microtitration wells 114 
coated with the recombinant treponemal antigens Tp15, Tp17, Tp47 and TmpA. After incubation 115 
with the test serum, bound IgM antibodies are detected with an enzyme-labelled anti-human-116 
IgM antibody. For the Euroimmun Anti-Treponema-pallidum-ELISA (IgM), prior to incubation 117 
with the test serum, interfering IgG antibodies are precipitated with anti-human-IgG antibodies. 118 
Results are calculated as index values (optical density of sample/cut-off value) and are then 119 
classified as negative (<0.8), equivocal (≥0.8, <1.1) or positive (≥1.1).  120 
According to the manufacturer’s protocol for the recomWell a pre-adsorption of IgG antibodies 121 
must not be done. However, due to moderate performance all samples were also tested with a 122 
modified recomWell Treponema IgM protocol in which interfering IgG antibodies were 123 
precipitated with Gullsorb reagent (Meridian Bioscience, Ohio, United States) containing anti-124 
human-IgG antibodies according to the manufacturer’s protocol. For the recomWell Treponema 125 
IgM, results are calculated as antibody units per ml (optical density of sample/cut-off value x 20) 126 
and are then classified as negative (<20), equivocal (≥20, ≤24) or positive (>24).  127 
In the Pathozyme Syphilis M Capture EIA microtitration wells are coated with anti-human 128 
IgM which captures IgM antibodies in the test serum onto the well. After washing a conjugate of 129 
native T. pallidum antigen (Tp15, Tp17, Tp44 and Tp47) labelled with horseradish peroxidase is 130 
applied. Results are calculated as index values (optical density of sample/cut-off value) and are 131 
then classified as negative (<0.9), equivocal (≥0.9, ≤1.1) or positive (>1.1). 132 
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Equivocal results of any of the specific IgM EIAs were repeated and the second result 133 
was accepted as the final one. Thus, 27 positive sera and 5 control sera had to be repeated, 134 
i.e., 14 Euroimmun, 6 recomWell, and 12 Pathozyme tests. In 10, 12, and 10 cases, 135 
respectively, results became negative, became positive, or remained equivocal upon repetition. 136 
Repeated equivocal results were considered as positive for calculating sensitivity and 137 
specificity. 138 
 139 
Statistical analysis 140 
Confidence intervals were calculated with GraphPad Prism, Version 5.04 (GraphPad Software, 141 
Inc., La Jolla, California). Sensitivities were compared with the McNemar Χ2 test16 online at 142 
http://graphpad.com/QuickCalcs (GraphPad Software, Inc., La Jolla, California last accessed 143 
9th January 2013).  144 
 145 
 146 
Results 147 
Results of all tests are shown in Tables 2 and 3 and corresponding sensitivities and specificities 148 
are depicted in Table 4.  In 148/156 patients the TPPA test was positive and in 8/156 it was 149 
equivocal/indeterminate. The VDRL test was positive or equivocal in 36/59 (61%) patients with 150 
primary syphilis, positive in 64/66 (97%) patients with secondary syphilis, in 24/25 (96%) 151 
patients with latent syphilis and in all six patients with tertiary syphilis. VDRL and TPPA titres 152 
were lower in primary syphilis compared to secondary, latent or tertiary syphilis (Table 2). 153 
The IgM-specific EIAs started with low to moderate high scores in primary syphilis and 154 
had a peak in secondary and to a lesser extent in tertiary syphilis, while in latent syphilis the 155 
scores were lowest (Table 2). A total of 138 (88.5%), 100 (64.1), and 132 (84.6%) of 156 sera of 156 
syphilis patients were tested positive by the IgM-specific Pathozyme, recomWell, and 157 
Euroimmun tests, respectively (Tables 2 and 4). As the recomWell Treponema IgM initially 158 
showed moderate performance all specimens were retested with a modified protocol what 159 
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resulted in a significantly (McNemar Χ2 = 11.5, p < 0.001) higher sensitivity (73.7% as opposed 160 
to 64.1%).  161 
In primary syphilis (Table 4), the sensitivities (% sensitivity, 95% CI) of the Pathozyme 162 
(89.8%, 79.2-96.2%) and the Euroimmun test (81.4%, 69.1-90.3%) were significantly higher 163 
than the sensitivities of the VDRL (61%, 47.4-73.5%) and the modified recomWell test (62.7%, 164 
49.2-75.0%) as assessed by the McNemar Χ2 test (Χ2 > 3.841, p < 0.05) 16. 165 
23/59 primary syphilis patients had a negative VDRL. These patients probably had early 166 
infection as the TPPA titres (median 1:320, interquartile range <1:80 – 1:320) were low, too. In 167 
this group, IgM-specific Pathozyme, modified recomWell, and Euroimmun tests were positive in 168 
22/23, 10/23, and 17/23 cases, respectively. Detailed results of seven patients with 169 
indeterminate TPPA are summarized in Table 5; in all of them syphilis was confirmed with later 170 
control sera, i.e., TPPA became positive and IgM EIA tests decreased after therapy. It is 171 
therefore believed that they had very early infection. Pathozyme, modified recomWell, and 172 
Euroimmun tests were positive or equivocal in 7/7, 2/7 and 3/7 cases, respectively. 173 
The specificity of all tests ranged from 91.4-100% (Tables 3 and 4). All investigated 174 
specific IgM tests showed some cross-reactivity, especially the Euroimmun Anti-Treponema-175 
pallidum-ELISA had difficulties with sera containing IgM antibodies against human Herpes 176 
viruses (7/10 anti-Epstein-Barr virus IgM sera and 3/10 anti-Cytomegalovirus IgM sera). 177 
 178 
 179 
Discussion 180 
The clinical and laboratory diagnosis of primary syphilis can be difficult.  Usually one or multiple, 181 
painless and indurate ulcers develop at the site of infection. However, the lesion may be 182 
atypical,1,17 e.g., i) only a papular lesion may develop, ii) it may be inconspicuous, iii) it does not 183 
develop in every case, iv) a syphilitic balanitis of Follman may be the only clinical expression. 184 
Patients might also seek medical advice after risk situations in the incubation period before 185 
development of clinical symptoms. Besides dark-field microscopy, which requires experienced 186 
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staff and is labour-intensive, and molecular tests, which are not yet generally used and are 187 
expensive, serological tests remain the most important tool for diagnosing syphilis. In the 188 
present study, and in those of others,4,5 the TPPA was the most sensitive single test in all 189 
stages of disease, confirming its suitability as a screening test.1 The VDRL test sensitivity was 190 
only 61% for primary syphilis, which is similar to what we found previously (58%)2 but somewhat 191 
lower than what other studies reported (66-87%).3,18,19 The sensitivity of the IgM-specific syphilis 192 
EIA assays for detecting primary syphilis was 89.8% for the Pathozyme Syphilis M Capture 193 
(Omega Diagnostics) test and 81.4% for the Anti-Treponema-pallidum-ELISA (IgM; 194 
Euroimmun). This was significantly higher than 62.7% of the modified recomWell Treponema 195 
IgM (Mikrogen) or 61% of the VDRL test. In secondary syphilis which corresponds to the 196 
hematogenic spreading of the pathogen throughout the entire body the EIAs had their highest 197 
sensitivities, whereas in latent syphilis which clinically is a silent period IgM EIA values were low 198 
and many samples were negative. 199 
Most interestingly is the group of primary syphilis patients with negative VDRL. These 200 
23/59 (39%) cases all would have been missed when the VDRL was used as the only first-line 201 
screening test as previously recommended in the United States.18,20 In this subgroup, the TPPA 202 
was positive in 17/23 and indeterminate in 6/23 cases. TPPA alone would have allowed 203 
diagnosing present or past syphilis infection in these cases (still, the six indeterminate cases 204 
would have been doubtful requiring confirmation with second samples). However, the 205 
combination of TPPA and IgM-specific EIA assays allowed correct diagnosis of early primary 206 
syphilis in 22/23 and 17/23 cases with the Pathozyme and the Euroimmun assay, respectively. 207 
The Pathozyme assay was even positive in seven cases with presumed very early infection with 208 
some patients eventually still being in the incubation phase (Table 5). It has been previously 209 
shown that a specific IgM EIA may be the only positive test in early infection.2,5 It is therefore 210 
suggested that in cases of suspected early infection specific IgM EIAs should be used in 211 
addition to other screening tests.1 It is important that clinicians communicate the suspicion of 212 
early infection to the laboratory in order that an IgM EIA is utilized. 213 
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Most previous studies investigating IgM-specific commercial assays have examined the 214 
Mercia Syphilis M EIA (Microgen Products Ltd),4,5,8-12 in one study the Eti-syphilis-M was 215 
analysed (DiaSorin).7 The reported sensitivities are similar to the ones found here, for primary 216 
syphilis they were in the range of 82-94% and for secondary syphilis in the range of 60-100%. 217 
For latent syphilis the sensitivity was dependent on whether early (56-87%) or late (0-50%) 218 
latent cases were examined. In one previous study the recomWell Treponema IgM assay was 219 
investigated,13 the sensitivity in 19 primary syphilis cases was 89.5% which is higher than in the 220 
present work. However, the assay was negative in all samples of later stages of syphilis. 221 
Schmidt et al.10 evaluated nine commercially available EIAs with a panel of 52 highly selected 222 
sera from primary syphilis patients, all negative with the microhemagglutination test for 223 
T. pallidum. Eight assays were designed to detect IgG alone or in combination with IgM 224 
antibodies. Most interestingly, the one assay detecting only IgM antibodies (Mercia Syphilis M 225 
EIA) demonstrated the highest sensitivity (86.5%) as compared to the other tests (22.6-76.9%). 226 
Remarkable is the fact that all these previous studies except two did not report the 227 
specificity. Ijsselmuiden et al.8 tested 48 samples of mainly treated syphilis patients and non-228 
infected neonates with a specificity of 98% and Sambri et al.13 tested 200 samples from blood-229 
donors and 60 samples from patients with possibly cross-reactive conditions (e.g. Lyme 230 
disease, mononucleosis, pregnancy) with 100% specificity. In the present study, 151 sera 231 
including 71 potentially cross-reactive samples were investigated for testing the specificity. 232 
Except for the Euroimmun assay which had some difficulties with sera which were positive for 233 
IgM antibodies against human Herpes viruses, all other assays showed specificities of 95.4-234 
100%.  235 
For monitoring the treatment response primarily non-treponemal tests such the VDRL or 236 
the RPR are recommended.1,3 It has been shown previously that specific IgM EIAs are a reliable 237 
supplement2,21,22 and this might be especially valuable in cases with an initially negative VDRL 238 
test (mainly primary syphilis cases) and in case of a slow decline or persisting low VDRL 239 
reactivity despite adequate therapy. However, it has to be noted that response rate may be 240 
different among different commercial IgM EIAs and also different as compared to the VDRL. 241 
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Studies which used the Mercia Syphilis M EIA reported negative test results one year after 242 
treatment in 92-100% of patients presenting with early syphilis21,22 - as compared to 62-87% in a 243 
study using the Pathozyme test.2 244 
All three IgM tests are easy to perform and do not require special equipment or special 245 
skills and knowledge of the staff. They have total incubation times of 2-2.5 hours and can be 246 
executed routinely within half a day. The tests differ, however, in their accuracy with the 247 
recomWell being the least sensitive. The recomWell assay is an indirect ‘sandwich’ EIA. In this 248 
kind of assay patients IgG antibodies are usually precipitated with an anti-human IgG antibody 249 
to avoid a competition with IgM antibodies in binding to the recombinant antigens what can 250 
cause a false-negative result. This step is missing in the recomWell procedure. Therefore, a 251 
modified recomWell protocol precipitating interfering IgG antibodies was tested. The sensitivity 252 
thus significantly increased from 64.1 to 73.7%. This demonstrates that the pre-adsorption of 253 
interfering IgG antibodies increases the performance. With some optimization of the protocol the 254 
sensitivity might be increased even more. 255 
A limitation of this study is the fact that the sera were stored at -20°C until testing with 256 
the Euroimmun and the recomWell assay. It cannot be entirely excluded that this might have 257 
influenced the result in some cases.  258 
In summary, specific syphilis IgM EIA assays are highly sensitive in primary syphilis and 259 
are specific. It is suggested that in cases of suspected early infection specific IgM EIAs should 260 
be used in addition to other screening tests. Additionally, they allow differentiation of active and 261 
past infection and may be used as supplement for monitoring treatment response. EIAs from 262 
different manufacturers vary in their performance.  263 
 264 
 265 
Addendum 266 
During the course of this study Omega Diagnostics informed that the Pathozyme Syphilis M 267 
Capture test is suspended from production until further notice. 268 
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